Neurophysiological Study of Peripheral Neuropathy after High-Dose Paclitaxel: Lack of Neuroprotective Effect of Amifostine

Clinical Cancer Research

Volumn 10, Issue 2, 2004, Pages 461-467

  Openshaw, Harry ^a   Beamon, Karen ^a   Synold, Timothy W ^a   Longmate, Jeff ^a   Slatkin, Neal E ^a   Doroshow, James H ^a   Forman, Stephen ^a   Margolin, Kim ^a   Morgan, Robert ^a   Shibata, Stephen ^a   Somlo, George ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; NEUROPROTECTIVE AGENT; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACHILLES REFLEX; ADULT; AREA UNDER THE CURVE; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW TOXICITY; BREAST CANCER; CARDIOTOXICITY; CLINICAL ARTICLE; COLD SENSATION; COMPOSITE PERIPHERAL NEUROPATHY SCORE; COMPOUND MUSCLE ACTION POTENTIAL; CONSTITUTIONAL SYMPTOM; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG MEGADOSE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG TOXICITY; MUSCLE ACTION POTENTIAL; MUSCULOSKELETAL DISEASE; NERVE CONDUCTION; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROLOGIC EXAMINATION; NEUROPROTECTION; PAIN; PARESTHESIA; PERCEPTIVE THRESHOLD; PERIPHERAL NEUROPATHY; PERONEUS NERVE; PRIORITY JOURNAL; SCORING SYSTEM; SENSORY NERVE ACTION POTENTIAL; SENSORY SYSTEM ELECTROPHYSIOLOGY; SENSORY SYSTEM EXAMINATION; SINGLE DRUG DOSE; SURAL NERVE; SYMPTOM; VIBRATION SENSE;

ADULT; AMIFOSTINE; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG SYNERGISM; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MIDDLE AGED; NARCOTICS; NEURONS; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; RADIATION-PROTECTIVE AGENTS; TIME FACTORS;

EID: 10744221369     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0772-03     Document Type: Article

References (29)

1. Lipton, R. B., Apfel, S. C., Dutcher, J. P., Rosenberg, R., Kaplan, J., Berger, A., Einzig, A. I., and Wiernik, P., and Schaumburg, H. H. Taxol produces a predominantly sensory neuropathy. Neurology, 39: 368-373, 1989.
2. Iniguez, C., Larrode, P., Mayordomo, J. I., Gonzalez, P., Adelantado, S., Yubero, A., Tres, A., and Morales, F. Reversible peripheral neuropathy induced by a single administration of high-dose paclitaxel. Neurology, 51: 868-870, 1998.
3. Chaudhry, V., Rowinsky, E. K., Sartorius, S. E., Donehower, R. C., and Cornblath, D. R., Peripheral fieuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann. Neurol., 35: 304-311, 1994.
4. Forsyth, P. A., Balmaceda, C., Peterson, K., Seidman, A. D., Brasher, P., and DeAngelis, L. M., Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J. Neurooncol., 35: 47-53, 1997.
5. Postma, T. J., Hoekman, K., van Riel, J. M., Heimans, J. J., and Vermorken, J. B., Peripheral neuropathy due to biweekly paclitaxel, epirubicin and cisplatin in patients with advanced ovarian cancer. J. Neurooncol., 45: 241-246, 1999.
6. Somlo, G., Doroshow, J. H., Synold, T., Longmate, J., Reardon, D., Chow, W., Forman, S. J., Leong, L. A., Margolin, K. A., Morgan R. J., Jr, Raschko, J. W., Shibata, S. I., Tetef, M. L., Yen, Y., Kogut, N., Schriber, J., Alvarnas J. High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome. Br. J. Cancer, 84: 1591-1598, 2001.
7. Vahdat, L. T., Papadopoulos, K., Balmaceda, C., McGovern, T., Dunleavy, J., Kaufman, E., Fung, B., Garrett, T., Savage, D., Tiersten, A., Ayello, J., Bagiella, E., Heitjan, D., Antman, K., and Hesdorffer, C. Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer. Clin. Cancer Res., 4: 1689-1695, 1998.
8. Vahdat, L., Papadopoulos, K., Lange, D., Leuin, S., Kaufman, E., Donovan, D., Frederick, D., Bagiella, E., Tiersten, A., Nichols, G., Garrett, T., Savage, D., Antman, K., Hesdorffer, C. S., and Balmaceda, C. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin. Cancer Res., 7: 1192-1197, 2001.
9. Liu, T., Liu, Y., He, S., Zhang, Z., and Kligermani, M. M., Use of radiation with or without WR-2721 in advanced rectal cancer. Cancer (Phila.), 69: 2820-2825, 1992.
10. Cagnoni, P. J., Jones, R. B., Bearman, S. I., Ross, M., Hami, L., Franklin, W. A., Capizzi, R., Schein, P. S., and Shpall, E. J. Use of amifostine in bone marrow purging. Semin. Oncol., 23: 44-48, 1996.
11. Ghielmini, M., Van der Bosch, S., Bosshard, M., Pampallona, S., Gabutti, L., Egger, H. P., Kiess, M., Cavalli, F., and Sessa, C. phase I-II study of escalating doses of amifostine combined with high-dose cyclophosphamide. Cancer Chemother. Pharmacol., 47: 532-536, 2001.
12. Petrilli, A. S., Oliveira, D. T., Ginani, V. C., Kechichian, R., Dishtchekenian, A., Filho Wde, M., Tanaka, C., Dias, C. G., Latorre Mdo, R., Brunetto, A. L., Cardoso, H., Almeida, M. T., and de Camargo, B. Use of amifostine in the therapy of osteosarcoma in children and adolescents. J. Pediatr. Hematol. Oncol., 24: 188-191, 2002.
13. Capizzi, R. L., The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin. Oncol., 26: 3-21, 1999.
14. Kurbacher, C. M., and Mallmann, P. K., Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721). Anticancer Res., 18: 2203-2210, 1998.
15. DiPaola, R. S., and Schuchter, L., Neurologic protection by amifostine. Semin. Oncol., 26: 82-88, 1999.
16. Kemp, G., Rose, P., Lurain, J., Berman, M., Manetta, A., Roullet, B., Homesley, H., Belpomme, D., and Glick, J. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J. Clin. Oncol., 14: 2101-2112, 1996.
17. DiPaola, R. S., Rodriguez, R., Goodin, S., Recio, I. A., Orlick, M., Mollnear, J., Bird, S., Belsh, J., Aisner, J., and Schuchter, L. Amifostine and dose intense paclitaxel in patients with advanced malignancies. Cancer Ther., 1: 11-17, 1998.
18. Gelmon, K., Eisenhauer, E., Bryce, C., Tolcher, A., Mayer, L., Tomlinson, E., Zee, B., Blackstein, M., Tomiak, E., Yau, J., Batist, G., and Fisher, B., and Iglesias J. Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J. Clin. Oncol., 17: 3038-3047, 1999.
19. Rick, O., Beyer, J., Schwella, N., Schubart, H., Schleicher, J., and Siegert, W., Assessment of amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor. Ann. Oncol., 12: 1151-1155, 2001.
20. Somlo, G., Sniecinski, I., Odom-Maryon, T., Nowicki, B., Chow, W., Hamasaki, V., Leong, L., Margolin, K., Morgan R Jr, Raschko, J., Shibata, S., Tetef, M., Molina, A., Berenson, R. J., Forman, S. J., and Doroshow, J. H. Effect of CD34+ selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancer. Blood, 89: 1521-1528, 1997.
21. Dyck, P. J., Zimmerman, I., Gillen, D. A., Johnson, D., Karnes, J. L., and O'Brien, P. C., Cool, warm, and heat-pain detection thresholds: testing methods and inferences about anatomic distribution of receptors. Neurology, 43: 1500-1508, 1993.
22. Rizzo, J., Riley, C., von Hoff, D., Kuhn, J., Phillips, J., and Brown, T., Analysis of anticancer drugs in biological fluids: determination of taxol with application to clinical pharmacokinetics. J. Pharm. Biomed. Anal., 8: 159-164, 1990.
23. Papadopoulos, K. P., Egorin, M. J., Huang, M., Troxel, A. B., Kaufman, E., Balmaceda, C. M., Vahdat, L. T., and Hesdorffer, C. S. The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. Cancer Chemother. Pharmacol., 47: 45-50, 2001.
24. Czejka, M., Schueller, J., Eder, I., Reznicek, G., Kraule, C., Zeleni, U., and Freitag, R. Clinical pharmacokinetics and metabolism of paclitaxel after polychemotherapy with the cytoprotective agent amifostine. Anticancer Res., 20: 3871-3877, 2000.
25. Van den Brande, J., Nannan Panday, V. R., Hoekman, K., Rosing, H., Huijskes, R. V., Verheijen, R. H., Beijnen, J. H., and Vermorken, J. B. Pharmacologic study of paclitaxel administered with or without the cytoprotective agent amifostine, and given as a single agent or in combination with epirubicin and cisplatin in patients with advanced solid tumors. Am. J. Clin. Oncol., 24: 401-403, 2001.
26. Schüller, J., Czejka, M., Pietrzak, C., Springer, B., Wirth, M., and Schernthaner, G. Influence of the cytoprotective agent amifostine on pharmacokinetics of paclitaxel and taxotere. Proc. Am. Soc. Clin. Oncol., 16: 224a, 1997.
27. Freyer, G., Hennebert, P., Awada, A., Gil, T., Kerger, J., Selleslags, J., Brassinne, C., Piccart, M., and de Valeriola, D. Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. Clin. Cancer Res., 8: 95-102, 2002.
28. Postma, T. J., Heimans, J. J., Muller, M. J., Ossenkoppele, G. J., Vermorken, J. B., and Aaronson, N. K., Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann. Oncol., 9: 739-744, 1998.
29. Slevin, M. L., Plant, H., Lynch, D., Drinkwater, J., and Gregory, W. M., Who should measure quality of life, the doctor or the patient? Br. J. Cancer, 57: 109-112, 1988.